| Patient | Frédéric Chopin |
|---|---|
| Date of birth | 1998-03-01 |
| Identifiers | MRN HR-NI020-SYN; SSN (made up) 000-20-8845 |
| Document date | 2026-09-15 |
| Author | Matthias Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; no new complaints. [S]
Mr. Chopin returns for his adult preventive visit eight weeks after completing tuberculosis treatment. He has had no cough, fever, night sweats, or weight loss since, and he has gained another 1.2 kg. He teaches his full schedule of about fifteen students a week and is preparing a small recital. He has a glass of wine with dinner a few times a week and has never smoked. His mood is good. He completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 28 |
| Active conditions | Pulmonary tuberculosis, treatment completed; malnutrition resolved |
| Medicines | None since tuberculosis treatment ended |
| Functional status | Independent; teaching full time |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, much better than in the spring |
| Psychosocial | Supported by friends from home and by his students; he told his students about the illness and none left |
| Behavioral | A glass of wine with dinner a few times a week (AUDIT-C 2); no tobacco or other drugs |
| Nutrition | Three meals and two snacks a day; no supplement drinks since August |
| Physical activity | Walks about 30 minutes most days |
| Activities of daily living | Independent in all |
| Sleep | About seven hours a night; no night sweats |
| Safety | No firearms; smoke detector working; wears a seat belt |
| Hearing and vision | No concerns |
| Sexual health | Discussed privately; no concerns |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No sore throat or hoarseness |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough, sputum, hemoptysis, or breathlessness |
| Gastrointestinal | Negative | No abdominal pain, greasy stools, or change in bowel habit |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No tendon or joint pain |
| Integumentary | Negative | No rash |
| Neurological | Negative | No numbness or tingling in his fingers |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 2026-03-20 to 2026-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-15 | Body height | 170 | cm | S |
| 2026-09-15 | Body weight | 56.2 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 70 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-15 | Total score [AUDIT-C] | 2 | {score} | S |
Vital signs recorded on 2026-09-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; slim; BMI 19.4 |
| Eyes | Conjunctivae normal |
| Ears, nose, and throat | Normal; no nasal polyps |
| Neck | No lymph nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear; no crackles |
| Abdomen | Soft; liver not enlarged |
| Extremities | No clubbing |
| Skin | No rash or suspicious lesions |
| Neurological | Normal sensation and fine finger movements |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed | R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
| Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 2026-2027 | Completed today | Given today |
| COVID-19 vaccine, 2026-2027 | Due | Recommended; he will get it at his pharmacy |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap about three years ago |
| Hepatitis B vaccine | Up to date | Immune by surface antibody at the tuberculosis diagnosis |
| HPV vaccine | Up to date | Series completed in adolescence by his report |
| HIV screening | Up to date | Negative at the tuberculosis diagnosis |
| Hepatitis C screening | Up to date | Antibody negative at the tuberculosis diagnosis |
| Tuberculosis testing | Not indicated | Treated for active tuberculosis; the blood test stays positive; symptom review instead |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 2, below the risk threshold |
| Tobacco use | Completed today | Never used |
| Blood pressure screening | Completed today | 112/70 mmHg |
| Diabetes screening | Not indicated | Recommended from 35 for adults with overweight or obesity; BMI 19.4 |
| Sexual health and STI screening | Completed today | Discussed privately; no screening indicated by his history |
Immunizations given today: Influenza vaccine, 2026-2027 season [S]
Guideline basis: Depression and Suicide Risk in Adults: Screening (2023); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Next preventive visit in one year; same-day visit for symptoms of relapse. [S]
Brief voluntary discussion, offered because of this year's serious illness. He wants to think about whom to name as his health care agent and was given the state's health care directive form. No treatment preferences are recorded. [S]